Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044413 | 0.83 | PTGS2 (0.53) | PTGS2LMNAALDH1A1HTTKDM4E | |
| SCHEMBL18102200 | 0.81 | LMNA (0.36) | MAPTPTGS2LMNAALDH1A1HTT | |
| SCHEMBL11356386 | 0.81 | PTGS2 (0.42) | MAPTPTGS2LMNAALDH1A1HTT | |
| SCHEMBL10044416 | 0.80 | PTGS2 (0.43) | PTGS2LMNAALDH1A1HSD17B10 | |
| SCHEMBL9362665 | 0.78 | HRH3 (0.36) | GAAMAPTPTGS2LMNAALDH1A1 | |
| SCHEMBL7926564 | 0.78 | GAA (0.44) | GAAPTGS2LMNAHTTMMP2 | |
| SCHEMBL9465765 | 0.78 | PTGS2 (0.38) | MAPTPTGS2LMNAALDH1A1HTT | |
| SCHEMBL14074048 | 0.78 | PTGS2 (0.38) | MAPTPTGS2LMNAALDH1A1HTT | |
| SCHEMBL14074024 | 0.78 | SMN1; SMN2 (0.41) | PTGS2LMNAALDH1A1MMP2MMP3 | |
| SCHEMBL14446918 | 0.78 | LMNA (0.59) | GAAMAPTLMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9216180-B2 | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay | NEW YORK UNIVERSITY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216180-B2 | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay | NEW YORK UNIVERSITY (US) | 2015-12-22 | — | — | US | disclosed |
| EP-1700856-B1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8889718-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20130267509-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8420827-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-09-11 | — | — | US | disclosed |
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-09-11 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267509-A1 | THIAZOLE DERIVATIVES | THRA, CHD8, CYP2C8 | GAA 2742/4885MAPT 1492/4885PTGS2 1832/4885 |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | CHD8, CYP2C8, THRA | GAA 3946/4885MAPT 4205/4885PTGS2 1849/4885 |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | GAA 3018/4885MAPT 4006/4885PTGS2 2268/4885 |
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | CYP11B2, CYP11B1, GRIN2A | GAA 3365/4885MAPT 549/4885PTGS2 1386/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | GAA 3099/4885MAPT 476/4885PTGS2 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.